The future of pediatric hepatocellular carcinoma: A combination of surgical, locoregional, and targeted therapy. / Weeda, V. ola B.; Murawski, Maciej.
In: Hepatoma Research, Vol. 7, 43, 2021.Research output: Contribution to journal › Article › Academic › peer-review
}
TY - JOUR
T1 - The future of pediatric hepatocellular carcinoma: A combination of surgical, locoregional, and targeted therapy
AU - Weeda, V. ola B.
AU - Murawski, Maciej
N1 - Publisher Copyright: © The Author(s) 2021.
PY - 2021
Y1 - 2021
N2 - Despite hepatocellular carcinoma’s position as the second most common pediatric liver tumor, it is a rare tumor in children warranting international collaboration to improve outcomes. Few cases diagnosed in earlier stages, when confined to the liver and responding to systemic treatment or with resectable metastases, may be cured by complete resection and/or orthotopic transplantation. Complete resection is the only chance for cure; therefore, all attempts should be made to make these options available. Despite modest progress in locoregional treatments, these serve in most cases as palliative treatment or as a bridge to definitive treatment at best. Currently used systemic treatments have response rates below 50%. Five-year survival in advanced stages is below 30%. The international Paediatric Hepatic International Tumour Trial trial is evaluating novel systemic treatments in pediatric hepatocellular carcinoma. Patients suffering from these tumors likely benefit from targeted treatment based on molecular aberrations corresponding with tumor subtype.
AB - Despite hepatocellular carcinoma’s position as the second most common pediatric liver tumor, it is a rare tumor in children warranting international collaboration to improve outcomes. Few cases diagnosed in earlier stages, when confined to the liver and responding to systemic treatment or with resectable metastases, may be cured by complete resection and/or orthotopic transplantation. Complete resection is the only chance for cure; therefore, all attempts should be made to make these options available. Despite modest progress in locoregional treatments, these serve in most cases as palliative treatment or as a bridge to definitive treatment at best. Currently used systemic treatments have response rates below 50%. Five-year survival in advanced stages is below 30%. The international Paediatric Hepatic International Tumour Trial trial is evaluating novel systemic treatments in pediatric hepatocellular carcinoma. Patients suffering from these tumors likely benefit from targeted treatment based on molecular aberrations corresponding with tumor subtype.
KW - Hepatocellular carcinoma
KW - Liver transplantation
KW - Liver tumor
KW - Locoregional treatment
KW - Pediatric
KW - Surgery
KW - Targeted treatment
UR - http://www.scopus.com/inward/record.url?scp=85114476569&partnerID=8YFLogxK
U2 - 10.20517/2394-5079.2021.10
DO - 10.20517/2394-5079.2021.10
M3 - Article
VL - 7
JO - Hepatoma Research
JF - Hepatoma Research
SN - 2394-5079
M1 - 43
ER -
ID: 19722494